“Evaluation of UHRF1 and P16INK4A expression levels in newly diagnosed AML patients”, Biomed. Res. Ther., vol. 5, no. 9, pp. 2658–2663, Sep. 2018, doi: 10.15419/bmrat.v5i9.475.